Australia markets open in 9 hours 59 minutes

Eton Pharmaceuticals, Inc. (ETON)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.3100+0.0600 (+1.85%)
As of 09:45AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.2500
Open3.2700
Bid3.2100 x 100
Ask3.4700 x 100
Day's range3.2700 - 3.3400
52-week range2.4200 - 5.8100
Volume6,795
Avg. volume62,698
Market cap85.028M
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

    PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024 earningsEstimated peak sales of more than $10 million annuallyU.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company foc

  • GlobeNewswire

    Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

    Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022Announced successful results from ET-400’s pivotal bioequivalence study, NDA submission planned for Q2 2024Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pha

  • GlobeNewswire

    Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

    DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here I